Skip to main content
SpringerLink
Log in

Gilead Sciences is cutting the prices of its antiretroviral HIV drugs by nearly two-thirds in middle-income countries

  • Media release
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. AIDS Healthcare Foundation.AHF Calls Gilead's Plan to Cut AIDS Drug Prices in Middle-income Countries by Two-thirds 'Precedent-setting'. Media Release: 17 Jul 2006. Available from: URL: http://www.aidshealth.org

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gilead Sciences is cutting the prices of its antiretroviral HIV drugs by nearly two-thirds in middle-income countries. Pharmacoecon. Outcomes News 508, 10 (2006). https://doi.org/10.2165/00151234-200605080-00032

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-200605080-00032

Keywords

Search

Navigation